{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:54:56Z","timestamp":1781643296654,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      the aim of this study is to investigate the safety profile and efficacy of single-dose docetaxel augmented targeted radionuclide therapy (TRT) in the form of prostate-specific membrane antigen (PSMA)- targeted radioligand therapy (RLT) using Lutetium-177 (177Lu) in patients who have progressed on PSMA-617 RLT. A retrospective analysis was conducted on 10 mCRPC patients (median age: 68 years; range: 51\u201374 years) who were progressing on prior RLT. The patients received one cycle of treatment involving 50\u00a0mg\/m\u00b2 of docetaxel combined with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617. Efficacy was assessed via biochemical (PSA, PCWG3) and molecular imaging endpoints (TLP\/MTV via [68Ga]Ga-PSMA-11 PET\/CT). PSA-progression-free survival (PSA-PFS) and overall survival (OS) were analyzed using Kaplan\u2013Meier statistics. Toxicity was graded by CTCAE v5.0.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After single-dose docetaxel augmented [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 RLT, 60% of the patients showed a disease stabilization for 4\u20138 weeks based on PSA (10% partial remission and 50% stable disease). Based on the molecular imaging-based response assessment, 62.5% of the patients showed a disease stabilization (25% parietal response and 37.5% stable disease). The median PSA-PFS and OS thereafter were 4.4 months (95%CI: 1.3\u20137.6 months) and 7.2 months (95%CI: 2.9\u201311.5 months), respectively. The augmentation therapy was well-tolerated without any serious acute adverse events. During the first 4\u20138 weeks thereafter 3 patients exhibited transient grade 3 anemia and one patient a transient grade 2 nephrotoxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This pilot experience demonstrates that single-dose docetaxel application to [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 radioligand therapy is feasible and may present an option for late-stage heavily pretreated mCRPC progressing on PSMA-617 RLT. Formal study of this combination is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-026-01408-w","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:25:08Z","timestamp":1773671108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome and safety of single-dose docetaxel\u2013augmented targeted radionuclide therapy using [\u00b9\u2077\u2077Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience"],"prefix":"10.1186","volume":"16","author":[{"given":"Niklas","family":"Ebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rosar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Blickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-7477","authenticated-orcid":false,"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1408_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05525-7","author":"F Khreish","year":"2021","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholom\u00e4 M, Ezziddin S. 177 Lu-PSMA-617 Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Initial 254-Patient Results from a Prospective Registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05525-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1408_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1408_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.14876","volume":"124","author":"MS Hofman","year":"2019","unstructured":"Hofman MS, Emmett L, Violet J, Zhang Y, Lawrence A, Stockler NJ, Francis M, Iravani RJ, Williams A, Azad S. TheraP: A Randomized Phase 2 Trial of 177 Lu-PSMA-617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration-Resistant Prostate Cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124(Suppl 1):5\u201313. https:\/\/doi.org\/10.1111\/bju.14876.","journal-title":"BJU Int"},{"key":"1408_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (TheraP): A Randomised, Open-Label, Phase 2 Trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"1408_CR5","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022;15:1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1408_CR6","doi-asserted-by":"publisher","unstructured":"Al-Ibraheem A, Abdlkadir AS, Sweedat DA, Maus S, Al-Rasheed U, Salah S, Khriesh F, Juaidi D, Abu Dayek D, Istatieh F et al. From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161\u00a0Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2024, 16, 1974. https:\/\/doi.org\/10.3390\/cancers16111974","DOI":"10.3390\/cancers16111974"},{"key":"1408_CR7","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, et al. Aggressive Variants of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2014;20:2846\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3309.","journal-title":"Clin Cancer Res"},{"key":"1408_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-Resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur Urol. 2021;79:343\u201350. https:\/\/doi.org\/10.1016\/j.eururo.2020.11.013.","journal-title":"Eur Urol"},{"key":"1408_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, Stemler T, Saar M, Bartholom\u00e4 M, Ezziddin S. Ac-PSMA-617\/177Lu-PSMA-617 Tandem Therapy of Metastatic Castration-Resistant Prostate Cancer: Pilot Experience. Eur J Nucl Med Mol Imaging. 2020;47:225. https:\/\/doi.org\/10.1007\/s00259-019-04612-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1408_CR10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/cancers14112691","volume":"14","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bader H, Bartholom\u00e4 M, Maus S, Burgard C, Linxweiler J, Khreish F, Ezziddin S. Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure-Preliminary Evidence of Pilot Experience. Cancers (Basel). 2022;14:2691. https:\/\/doi.org\/10.3390\/cancers14112691.","journal-title":"Cancers (Basel)"},{"key":"1408_CR11","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00259-025-07168-4","volume":"52","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Moghrabi S, Sathekge MM, Abdlkadir AS. Evaluating Xerostomia as a Side Effect of [255Ac]Ac-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-Analysis. Eur J Nucl Med Mol Imaging. 2025;52:2906\u201317. https:\/\/doi.org\/10.1007\/s00259-025-07168-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1408_CR12","doi-asserted-by":"publisher","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. JCO 2016, 34, 1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"1408_CR13","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med. 2009;50:S122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"1408_CR14","unstructured":"Common Terminology. Criteria for Adverse Events (CTCAE). 2017."},{"key":"1408_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee S-T, Ng S, Francis RJ, Goh JC, et al. [177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (ENZA-p): An Open-Label, Multicentre, Randomised, Phase 2 Trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"1408_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/cbr.2012.1276","volume":"27","author":"PG Claringbold","year":"2012","unstructured":"Claringbold PG, Price RA, Turner JH. Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors. Cancer Biother Radiopharm. 2012;27:561\u20139. https:\/\/doi.org\/10.1089\/cbr.2012.1276.","journal-title":"Cancer Biother Radiopharm"},{"key":"1408_CR17","doi-asserted-by":"publisher","unstructured":"Kesavan M, Claringbold PG, Turner JH. Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up. Neuroendocrinology 2014, 99, 108\u2013117. https:\/\/doi.org\/10.1159\/000362558","DOI":"10.1159\/000362558"},{"key":"1408_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, Guminski A, Francis RJ, Saghebi J, Dhiantravan N, et al. Sequential [177Lu]Lu-PSMA-617 and Docetaxel versus Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (UpFrontPSMA): A Multicentre, Open-Label, Randomised, Phase 2 Study. Lancet Oncol. 2024;25:1267\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(24)00440-6.","journal-title":"Lancet Oncol"},{"key":"1408_CR19","doi-asserted-by":"publisher","first-page":"848e9","DOI":"10.1016\/j.urolonc.2020.05.028","volume":"38","author":"JS Batra","year":"2020","unstructured":"Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, et al. Phase I Trial of Docetaxel plus Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Urol Oncol. 2020;38:848e9. 848.e16.","journal-title":"Urol Oncol"},{"key":"1408_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fl\u00e9chon A, Wei XX, et al. 177Lu-PSMA-617 versus a Change of Androgen Receptor Pathway Inhibitor Therapy for Taxane-Naive Patients with Progressive Metastatic Castration-Resistant Prostate Cancer (PSMAfore): A Phase 3, Randomised, Controlled Trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"1408_CR21","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Banks PD, Wallace R, Hamid A, Inderjeeth AJ, et al. LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). J Clin Oncol. 2023;41:5005\u20135005. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5005.","journal-title":"J Clin Oncol"},{"key":"1408_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13139-024-00871-4","volume":"58","author":"AS Abdlkadir","year":"2024","unstructured":"Abdlkadir AS, Abufara A, Al-Ibraheem A. Dual Radionuclide Therapy: The Synergistic Effects of [161\u00a0Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure. Nucl Med Mol Imaging. 2024;58:381\u20132. https:\/\/doi.org\/10.1007\/s13139-024-00871-4.","journal-title":"Nucl Med Mol Imaging"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-026-01408-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-026-01408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:12:30Z","timestamp":1781640750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13550-026-01408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1408"],"URL":"https:\/\/doi.org\/10.1186\/s13550-026-01408-w","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the local Institutional Review Board (ethics committee permission number 140\/17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients who participated in this study gave their written consent after being informed about risks and potential side effects of this therapy. All patients agreed to publication of their data in accordance with the declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}